{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-021266","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2022-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.243662+00:00","generated_at":"2026-06-25T07:26:01.018086+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FDA approves Tyvaso DPI using MannKind's Technosphere platform; availability June 2022","bullets":["Tyvaso DPI is second FDA-approved product using MannKind's Technosphere inhalation platform; first dry powder inhaled treatment for PAH and PH-ILD.","Manufacturing of Tyvaso DPI underway at MannKind's Connecticut facility; product availability expected in June 2022.","Commercial supply agreement with United Therapeutics runs through 2031; initially signed in August 2021.","Tyvaso DPI uses dry powder formulation and Dreamboat inhaler technology from Afrezza; convenient alternative to liquid nebulization."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-021266","json":"https://secwatch.observer/filing/0001564590-22-021266.json","markdown":"https://secwatch.observer/filing/0001564590-22-021266.md","text":"https://secwatch.observer/filing/0001564590-22-021266.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000156459022021266/0001564590-22-021266-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000156459022021266/mnkd-8k_20220524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T07:26:01.018086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}